Business News & Financial News

News Corp. has been beneficial in the fourth fiscal quarter thanks to strong performance of its cable networks and advertising revenue growth of its newspapers.

The media company posted a profit of 875 million, or 33 cents per share for the quarter ended June 30, against a loss of 203 million (eight cents per share) a year ago when News Corp recorded a asset impairment charge.

Turnover rose 5% to 8.11 billion dollars. The Thomson Reuters consensus I / B / E / S gave a turnover of 8.05 billion.

Action News Corp. gained 2.9% to 14.25 dollars after the close of Wall Street, in response to these results.It grew by 12% since the beginning of the year, while the S & P movies and entertainment took 8% in the same time.

Rebound in advertising revenue and lower costs led to a growth in operating income by 20% in the press in the U.S. and internationally. The operating profit of its cable division has increased 31%.

In contrast, there was decline results from the satellite television and commercial services, and loss of the digital divide, including social network MySpace.

In attempting to seize the biotech Genzyme, Sanofi-Aventis hopes to enter a segment long ignored by major pharmaceutical companies, one of rare diseases.

It would appear that the giants of the industry think that investing in this field can be a good way to increase margins, complete the range of products and at least partially offset the impact of competition from generic.

Pfizer and GlaxoSmithKline have already tried the adventure but the offer from Sanofi on Genzyme – which could turn around 14.3 billion euros – would be by far the most advanced.

Genzyme is the world leader in treatments for rare diseases.He realized in 2009 a turnover of around 4.5 billion dollars from drug dealing rare inherited disorders such as Gaucher and Fabry disease.

"Genzyme has demonstrated to all that the market for rare diseases can be quite profitable," said Gary Pisano, a professor at Harvard Business School and a specialist in biotechnology.

These drugs for rare diseases, so-called "orphan" can reach astronomical prices and yet are rarely rejected by insurance companies.Cerezyme, blockbuster treating Gaucher disease developed by Genzyme, is an annual treatment cost of over $ 200,000.

This is one of the drugs most expensive in the world and represented the last year a turnover of 1.2 billion dollars.

NEW PERSPECTIVES

They are new opportunities opening up for big pharmaceutical companies that are themselves, most often, little to offer in terms of experimental medicines.

"The era of 'blockbuster' seems gone," says Kevin Gorman (Putnam Associates). "In rare diseases needs to look far the greatest."

Gaucher disease and Fabry disease are characterized by an enzyme deficiency that can cause irreparable damage or even lethal to the organs.Treating such diseases is not accessible to all laboratories and even the big pharmaceutical companies are not equipped to start from scratch in this field.

Design in this field of rare diseases, clinical trials, control of complex manufacturing processes and finally market drugs in highly targeted markets, this requires a special skill mastery that Genzyme to perfection.

Yet, one case of infection occurred at the site last year Genzyme Allston Landing in Boston, led to a shortage of two key drugs and led to a sharp drop in results and a diving action.

Sanofi hopes to capitalize on woes Genzyme to buy cheap.It offers 69 dollars per share, according to sources familiar with the matter, much less than the $ 80 where work is changing before disorders occur manufacturing end of 2008.

According to sources, it is unlikely that Genzyme accepts less than 80 dollars per share. This can be explained by the fact that Genzyme is an asset as rare as the diseases it treats.

It is not likely to be subject to generic competition soon.It has also more than 20 years of experience in the relationship with patient groups in the organization of clinical trials and reimbursement management and regulatory issues.

NOT EASY TO COPY

"The reasons why large groups are eyeing this segment reduced threat of generic products, products that can be expanded to other areas and prices," said Dominic Valder, an analyst at Evolution Securities.

Traditionally, the big pharmaceutical companies focus on drugs prescribed by GPs in a large population of patients with chronic conditions like diabetes, depression, ulcers or cholesterol is too high.

These medicines are made from molecules that can easily replicate génériquiers.

The biotech drugs are on the contrary from protein complex. They are prescribed by specialists for patients in small numbers. They are not easy to copy.

Some heavyweights pharmacy try their luck but so timidly.For Patrick Vallance, head of research at Glaxo, the strategy aims to improve the returns to research and development focusing on areas where the probability of success are greatest.

Glaxo has taken a stake in the Japanese and JCR Pharmaceuticals has entered into an alliance with privately held Prosensa, leading to the launch of a Phase III clinical trial in the second half and bearing on Duchenne muscular dystrophy.

Pfizer has acquired worldwide rights to an experimental treatment for Gaucher disease developed by Protalix BioTherapeutics, which if approved, would compete with Genzyme's Cerezyme.

The International Monetary Fund forecasts growth of 1.4% in France this year, as the government, but is more cautious thereafter, and questions whether the government deficit back below 3% of GDP before 2015.

In its annual report on France on Friday, the IMF welcomed the "ambitious reform program" implemented by the authorities, welcomed the "major reform" of pensions and notes that French banks are strong, as the Recent tests have shown the organized resistance in the European Union.

But he stressed the risks to future growth, although France has fared better than its neighbors to the recession, and recommends giving priority to a "substantial and credible rebalancing" of public finances.

After a contraction of 2.5% in 2009, the institution sees gross domestic product of France grow 1.4% this year – the same prediction that the government – and by 1.6% in 2011, 1.8 % in 2012 and 2.0% in 2013.

These estimates are similar to those published in the April World Economic Outlook of the IMF, while those on the deficit is more optimistic.

After 7.5% in 2009 and 8.0% in 2010 (again forecasting government), the deficit would decrease to 6.1% of GDP in 2011.In April the IMF was around 7%.

"This is the result of a conference on fiscal deficits in July and pension reform in June," Harris says one in Bercy where we judge the IMF and Paris "on the same wavelength" .

"It's a good report of the IMF for economic policy the government," says one.

IMF WANTS THE ASSUMPTIONS OF "REALISTIC"

However, the IMF is the deficit to 3.9% of GDP in 2013 and, according to his script, is that in 2015 he would return below the 3% limit set by the Maastricht Treaty.

The stability program of France plans to achieve the 3% deficit in 2013, subject to a growth of 2.5% from next year.

"To make the effort of more credible, it is important to establish the framework for budgetary planning on realistic macroeconomic assumptions," the IMF in his notes, echoing criticism by the European Commission issued in March when he was sent to the stability program.

During a conference call, one of the reviewers, Erik de Vrij, however relativized this message indicating that the deficit target reduced to 3% in 2013 could be achieved if the pension reform is completed.

"By including the pension reform, there is a good chance of reaching 3% deficit by 2013," he said.

Published annually after the visit of a mission, the IMF notes is rather complimentary to the government's economic policy but calls for greater efforts on reforms and fiscal consolidation.

"A fragile recovery is underway in France," it said.

Her limited exposure to international trade, the existence of a strong enough financial sector, the importance of social safety nets and measures to relaunch "well designed" have enabled France to resist the global crisis that most comparable countries, the IMF noted.

But, he adds, 'the characteristics of the French economy, which have protected partly during the recession are also those who probably will slow the recovery.

"PUSHED MORE INITIATIVES"

The unemployment rate of 9.5% in 2009 to reach 10.0% on average this year and peaking at 10.1% in 2011, before easing to 9.7% in 2012 and 9.2% in 2013 according to the IMF.

At the same time, public debt would reach 84.3 in 2010% of GDP against 78.1% in 2009 and would continue to deteriorate until 2013, when this ratio reach 90.3%.

"The imminent consolidation of public finances in France and most European countries will weigh on demand, and concerns that continue to generate sovereign risk require continued vigilance," said the Fund, requesting the authorities to "implement with their energy reform program to support the recovery. "

On the fiscal consolidation policy, the IMF considers that the measures already announced on revenues and expenditures are "large" but said that "further efforts are needed at all levels of government to achieve fiscal consolidation is the medium term ".

The institution also delivers a good report on the reform of banking regulation, acknowledging in particular the establishment of the supervisory authority which has for the month of March all supervisors and approval of the bank and insurance in France.

Carphone Warehouse, the first European distributor of mobile phones, publishes quarterly results above its forecast, thanks to smartphone demand, pushing up the stock price of more than 5%.

The British group showed some caution about the economic climate but said he was confident, however, achieve its goal for the year in April.

Of the thirteen weeks to July 3, the first fiscal quarter, sales in stores open at least a year rose 3.7% at constant exchange rates in the European market.

This increase is greater than analysts' forecasts that anticipated growth of 2%, according to a survey conducted by the company.

Carphone has also said that the three new stores opened since April in Britain under the name Best Buy have been successful had a "very positive", without giving figures.

Asked by Reuters about the economic outlook, the group general manager Roger Taylor said: "I am not a prophet of doom. But I do not presume to rapid growth, either."

The title gained 5.09% to 227 pence at 10h00 GMT, the FTSE 100 yielded 0.19%.

DuPont publishes a quarterly profit nearly tripled thanks to a double digit growth in sales in its five main business segments.

The number three of the chemistry in the United States has achieved during April-June net profit of 1.17 billion (900 million euros), or $ 1.26 per share, against 417 million (41 cents / share) on the corresponding period last year.

Excluding items, earnings were $ 1.17 per share.

Financial analysts had expected earnings of 93 cents per share according to Thomson Reuters I / B / E / S.It was not clear immediately that this consensus is comparable to published results.

The quarterly revenue rose 25.6% to $ 8.62 billion against 8.27 billion expected by the market.

DuPont revised upwards its forecast range for the full year, saying it now expects earnings per share (EPS) of 2.90 to 3.05 dollars excluding special items, against 2.50 to 2.70 far.

The market consensus gives an annual EPS of 2.64 dollars.

The action DuPont, one of the 30 stocks in the Dow Jones gained 2.1% in pre-market transactions, to 39.80 dollars.

Wall Street could fall this week in a market upturn phase, but will require a new set of quarterly results convincing to feed the stock market rally that started in U.S. last weekend.

The markets have been digesting macroeconomic statistics found disappointing and pessimistic comments from Federal Reserve Chairman Ben Bernanke on the U.S. economy, but the announcement of strong quarterly results by companies suggest a brighter future.

But this week, others are expected quarterly publications such as the oil company Chevron, DuPont chemist or the aircraft manufacturer Boeing.Good news would reassure investors.

Investors have had to readjust their forecasts for the economy with the latest statistics that portend a slowdown in the pace of recovery.

These data have also created divisions in the markets about the possibility of a new recession.If the concerns of a return to "W" began to fade among investors, publications positive would result in rising markets.

FIGURES OF THE GROWTH EXPECTED

"All indicators continue to signal growth, simply we are not moving as quickly as when we came out of the recession, which is totally logical," said Michael O'Rourke, chief market strategist at BTIG LLC, adding that the downward phase of the contract is completed.

He considers in particular that the beginning of July should be the low point of annual contracts.

Analysts hope to cheer the quarterly results this week after figures better than expected and forecast annual improvements announced last week by industry groups.

But the economy remains crucial. The series of publications macroeconomic expected this week will also be particularly monitored to determine the strength of the U.S. economic recovery.

The Fed should publish its Beige Book Wednesday on the economic conditions, while the figures for new home sales will launch the week Monday.

On Tuesday, it is the Standard & Poor's / Case Schiller home prices and consumer confidence, which will be followed, before investors only look the next day on orders of durable goods.

But it was the day Friday with the first estimate of gross domestic product (GDP) U.S. second quarter to be expected this week.

The U.S. stock markets opened on a negative note Friday as investors show some nervousness before the publication of the results of resistance testing taxed at 91 European banks.

A few minutes after the start of trading, the Dow Jones yielded 0.28% to 10,293.16 points, the Standard & Poor's 500 index 0.44% to 1088.89 points and the Nasdaq Composite 0.51% to 2234.45 points.

Losses are limited by satisfactory business results and publication of European statistics reassuring, especially in Great Britain and Germany.

Microsoft and Ford have published better than expected, the reaction of titles respectively 0.23% and 3.31%.

In contrast, the Citigroup opens down 1.71% to 4.02 dollars, the U.S. Treasury prepares to sell 1.5 billion shares to reduce state participation in the U.S. bank, gained during the rescue group.

The Franco-Dutch Unibail-Rodamco, faced with a lackluster economic environment, will make the cash to shareholders to try to offset the stagnation of its results.

The leading European commercial real estate offers and distribute 1.8 billion euros in cash to shareholders, or 20 euros per share in respect of a return of capital, "he said Wednesday in release.

This operation, which takes the form of a refund procedure premium contribution, roughly the amount of sales, net of acquisitions made since the merger in 2007 between Unibail and Rodamco, the company said.

Unibail-Rodamco has sold four billion euros of assets since the merger and purchased 2.4 billion euros.

The transaction will be subject to an extraordinary general meeting on September 8 for a payment on October 12 and will be funded by four billion euros in credit lines.

Meanwhile, the company said it benefited from renewed investor interest in quality real estate assets to accelerate asset sales and further focus on its biggest shopping malls.

In seven months, Unibail-Rodamco has sold 1.2 billion euros of assets, with an average premium of 9% compared to their appraised values.It plans to sell another 500 million by the end of the year and 2.5 billion by 2012, the Netherlands, but also in France, Spain and Scandinavia.

The land group aims to reduce the number of shopping centers from 95 to 60 by 2012.

NO IMPROVEMENT FOR HIGH

This strategy of refocusing the group on its greatest asset and most cost reflects the uncertainty about the future growth and household consumption.

"I see no reason for a big improvement in overall consumption, but our schools should do better," said Guillaume Poitrinal, CEO, a few journalists."I'm not optimistic about the economic situation in France, but our particular positioning can help us gain market share," he added.

Some analysts also see it as an uncertainty about the continued recovery in property prices.

"Having to pay a special dividend and accelerate disposals may mean that the company does not believe too much in pursuit of the rising property market," commented one of them, who would not be identified.

The company has not yet abandoned its development projects and plans to invest 1.5 billion euros by 2015 to modernize its existing facilities and 5.7 billion for new projects, of which 1.3 billion are actually incurred.He did not rule out further acquisitions.

After the transaction, Unibail will remain the land the least indebted in Europe with a debt ratio increased from 31% to 40%.

Standard & Poor's revised after the announcement, his outlook on the company, which went from stable to negative, while confirming her an "A" long term "A-1 'short-term, and Fitch, which replaced Moody's at the request of the group has assigned a grade "A" long-term debt IDR (issuer default rating).

RESULTS NO SURPRISE

For the first half of 2010, Unibail-Rodamco has published a recurring earnings per share of 4.70 euros, up 0.4% in the first half of 2009, with net rental income of 624 million, down 1 6% (+0.4% at constant perimeter).

Its net asset liquidation stood at 131.00 euros per share, up 2.2% from late 2009 its assets increased by one billion euros to 23.3 billion, ending a two- year decline in the value of its assets.

According to a consensus calculated by the editor of Reuters estimates from a dozen analysts, estimates ranged to 4.51 euros for recurring earnings per share and 130.06 euros for the net asset value (NAV ).

The property has confirmed its growth target of zero to 2% of its recurring earnings per share in 2010, including the impact of capital repayment, after rising 7.1% in 2009, mainly because of low indexation of rents.

The single European property to be included in the Eurostoxx 50, with a market capitalization of 12.5 billion euros, closed up 2.79% in the Paris Bourse to 140.100 euros before the publication of these figures.

Since the beginning of the year, the security loses 8.8%, after rising 44% in 2009.

Manitou Tuesday reported a sharp rise in quarterly sales, but said the second half anticipate a slowdown in orders and a possible impact on delivery times its turnover.

The specialist said all terrain truck build for 2010 growth of 10% to 15% of its turnover, after announcing a 36% increase in sales in the second quarter to 225 million euros, 8.3% throughout the first half, to 387 million euros.

The backlog reached a record level of 5,400 machines at the end of June, said Manitou.

"We focus on our ability to issue orders in a fluid and operational chain still very tense," the group said in a statement.

Manitou has estimated that its order intake for the second quarter allowed him to secure part of his turnover for the second half, but the group expects a slowdown in the second half of the year.

"We continue to believe that these orders are from reports of investment in 2009, the natural cycles of replacement of machinery, and the traditional seasonal effect," the company said.

"However, we do not always signal a real recovery in volumes, either through rental building, expansion of agricultural markets or just a restocking distribution networks," Has added.

The action Manitou closed Tuesday up 1.30%, to 11.68 euros in a market capitalization of around 440 million euros.

Electrolux reported an operating profit below expectations for the second quarter and reaffirmed its forecast of a rise in demand this year in its main markets.

Operating income was 1.5 billion kronor (157 million) excluding exceptional items, against one billion kroner in the second quarter of 2009.The 17 banks and brokerages surveyed by Reuters had expected a net profit of 1.6 billion kronor for the period Apr-Jun 2010.

At 7:36 GMT, yielded 5.0% to 158.70 kronor on the Stockholm Stock Exchange.

"The demand for appliances on the group's main markets should be growing during 2010," the Swedish group in a statement.

The second largest manufacturer of household appliances has been forced to sharply reduce its costs to cope with the slowdown in consumption last year but said its main markets had continued to recover in the second quarter.

Electrolux said the North American market had risen for the third consecutive quarter after 13 quarters of contraction.

"At the industry level, the supply of aircraft destined for the United States in the second quarter would have increased approximately 10%," the group said.

"The entire European market has stabilized during the quarter, with major markets such as Germany, France and Sweden showing positive trends," he added, while noting that southern markets Europe had suffered a sharp slowdown over the period.

'The demand in eastern Europe has increased somewhat, further stated Electrolux.